Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BMS-986036 in Renal Impairment
NCT03674476Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2018
- Primary completion
- Jun 2019
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 1, open-label trial of pegbelfermin in Nonalcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed serum concentration of C-terminal intact BMS-986036 at 30 days, Time of maximum observed serum concentration of C-terminal intact BMS-986036 at 30 days and 8 more. Started Sep 2018; status: completed.
02
Drugs
pegbelfermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03674476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674476.